Tempus Pixel

by Tempus (formerly Arterys)  · Based in United States → — The future of precision medicine that only human + AI can achieve.
Cardiology Oncology Radiology

Contact for quote
Regulatory Status Disclosed

Overview

Tempus Pixel, originally developed by Arterys and now part of Tempus, is an AI-powered cloud-based medical imaging analysis platform. It is designed to integrate seamlessly into existing PACS or EHR workflows, enhancing the speed, efficiency, and accuracy of medical image interpretation. The platform leverages deep learning and cloud computation to provide advanced analysis across various modalities, including MRI, CT, and X-ray. It aims to reduce variability and subjectivity in clinical diagnoses, alleviate radiologist workloads, and improve patient outcomes by extracting actionable insights from medical images. Tempus Pixel offers solutions for a wide range of sub-specialties, including cardiology, oncology (liver, lung, breast), and neurology, with features like automated segmentation, quantitative analysis, and longitudinal tracking.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered analysis
  • Cloud-based platform
  • Real-time collaboration
  • Multi-modality support (MRI, CT, X-ray, ultrasound)
  • Automated reporting
  • 3D visualization
  • Quantitative analysis
  • DICOM compatibility
  • Customizable workflows
  • Scalable architecture
  • Data security
  • Integration with PACS, EHR, RIS
  • Automated segmentation
  • Clinical decision support
  • 4D Flow analysis
  • Nodule detection and tracking
  • Lesion identification and tracking
  • T1 and T2 inline map generation

Use Cases

  • Cardiac MRI analysis (4D flow, ventricular function, tissue characterization)
  • Lung nodule detection, quantification, and longitudinal tracking
  • Liver lesion analysis and tracking for oncology
  • Breast cancer detection, screening, and density assessment
  • Stroke detection on CT
  • Brain tumor diagnostics on MR
  • Therapy response evaluation

Details

Category Cardiology AI
Pricing Contact for quote
DeploymentCloud-based, web-based (accessible via Google Chrome browser), integrates with existing PACS, EHR, and RIS environments.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Tempus Pixel, and its preceding Arterys products, have received multiple 510(k) clearances from the U.S. Food and Drug Administration (FDA). This includes clearances for cardiac MR image analysis (Tempus Pixel Cardio), liver and lung oncology AI, and breast AI. A recent update in September 2025 for Tempus Pixel specifically allows for the generation of T1 and T2 inline maps for cardiac MR images, providing deeper insights into heart tissue characteristics.

Integrations
EHR Not specified
Specialties Cardiology, Oncology, Radiology

What the Web Says

Tempus Pixel is an AI-powered cardiac imaging platform that enhances medical imaging by analyzing scans, highlighting abnormalities, and generating actionable insights, with a focus on personalized patient care. It has received FDA clearance for its updated functionality, allowing it to generate T1 and T2 inline maps directly from raw MRI data. While some physicians praise Tempus's overall approach to precision medicine and its data platform, there are mixed reviews regarding customer service, the usability of genetic test results, and employee satisfaction.

Overall: Mixed

Strengths

  • AI-enabled precision medicine and genomic testing.
  • Enhances medical imaging by rapidly analyzing scans and highlighting abnormalities.
  • Generates T1 and T2 inline maps directly from raw MRI data for comprehensive tissue assessment.
  • Supports physicians in delivering personalized medicine and making data-driven decisions.
  • Offers a large library of clinical and molecular data.
  • Can improve diagnostic consistency and accelerate turnaround times in pathology.

Limitations

  • Genetic test results can be difficult to navigate and interpret for some users.
  • Reports of poor customer service, including unresponsiveness and difficulties with refunds.
  • Mixed employee reviews, with some citing a toxic work environment, poor work-life balance, and disorganized management.
  • Some physicians question the immediate benefit of certain Tempus tests if treatment plans are already established.
  • Concerns about the company's focus and potential for its own AI model development.
  • The Tempus Pro device for EMS has been criticized for being slow, unreliable, and lacking certain essential functionalities.

Based on reviews from: G2, Reddit, Capterra, Indeed.com, Tempus AI (Official Site), YouTube (Tempus Testimonials), AuntMinnie, Nebula Genomics, MarketBeat, Business Wire

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Tempus Pixel

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

AllMind AI News
Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging
Tempus AI received FDA 510(k) clearance for its updated Tempus Pixel cardiac imaging platform, which now generates T1 and T2 inline maps directly from raw MRI data. This advancement improves diagnostic accuracy and workflow efficiency for detecting conditions like fibrosis and edema.
2025-09
Tempus AI, Inc. (NASDAQ: TEM)
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
Tempus AI announced FDA 510(k) clearance for its updated Tempus Pixel, an AI-powered cardiac imaging platform that enhances cardiac MR image analysis by generating T1 and T2 inline maps. This improves efficiency and accuracy in detecting conditions like fibrosis, inflammation, or edema.
2025-09
Diagnostic Imaging
FDA Clears Updated AI Software for Generating Inline Mapping with Cardiac MRI
The FDA granted 510(k) clearance to the updated Tempus Pixel AI software, which provides T1 and T2 inline maps to enhance cardiac MRI assessment. This facilitates rapid assessment and improved insights into subtle abnormalities, aiding in the earlier detection of various cardiac conditions.
2025-09
ICE Magazine
Updated Tempus Pixel Device Receives FDA Special 510(k) Clearance
Tempus AI Inc. announced FDA 510(k) clearance for its updated Tempus Pixel, an AI-powered cardiac imaging platform that generates T1 and T2 inline maps from raw MRI data. This enhances cardiac MR image analysis, improving efficiency and accuracy in flow visualization, functional analysis, and tissue characterization.
2025-09
Tempus AI
Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform
Tempus AI collaborated with Median Technologies to integrate Median's eyonisu00ae LCS, an AI-based lung cancer screening software, into the Tempus Pixel platform. This integration aims to empower clinical workflows with tools for informed diagnostic and disease management decisions, particularly for lung cancer screening.
2026-02
Medical Design & Outsourcing
Tempus, Median Technologies Collaborate on AI-Powered Lung Cancer Screening
Tempus AI Inc. and Median Technologies are partnering to integrate eyonis LCS into the Tempus Pixel platform, enhancing lung cancer screening by enabling non-invasive characterization and risk stratification of lung nodules from CT images. This collaboration aims to improve early detection and patient care.
2026-04
Zacks Investment Research
Tempus AI's Diagnostics and Data Arms Drive Long-Term Growth Story
Tempus Pixel is highlighted as an imaging platform integrating AI into diagnostic workflows, with recent 510(k) clearances supporting broader use cases. This article emphasizes how regulatory milestones enable clinical deployment and strengthen Tempus's position with life sciences partners.
2026-03
Medical Horizons
Tempus Pixel & Medical Horizons Renew Successful Collaboration with 7-Year Distribution Agreement Extension in Italy
Medical Horizons and Tempus renewed their exclusive distribution agreement for the Tempus Pixel Radiology portfolio in Italy for another seven years. This collaboration includes Cardio, Lung, and Breast AI solutions, building on their longstanding relationship since Tempus's acquisition of Arterys.
2025-06

Videos

Product demos, reviews, and walkthroughs for Tempus Pixel.

Loading videos...

View all on YouTube

Frequently Asked Questions

Tempus Pixel Cardio is designed for seamless integration with existing PACS, EHR, worklist, notification, and dictation systems to optimize radiology workflows. It provides advanced viewing and automated reporting of cardiac MR images, aiming to improve efficiency and accuracy in various analyses.
Tempus Pixel Cardio analyzes cardiac MR images for flow visualization and quantification, functional analysis (e.g., cardiac chamber volumetry, ventricular function), and tissue characterization (e.g., T1, T2, T2* maps for fibrosis, inflammation, edema). It also offers AI-based myocardial strain analysis and can generate T1 and T2 inline maps directly from raw MRI data, providing numerical values for tissue characteristics.
Yes, Tempus Pixel Cardio has received FDA 510(k) clearance for its updated cardiac MR image analysis platform. While the search results confirm FDA clearance, specific details on HIPAA compliance are not explicitly detailed in the provided snippets, but as a healthcare AI company, Tempus would be expected to adhere to such regulations.
Tempus Pixel Cardio aims to improve efficiency and accuracy in cardiac MR image analysis, with reported reductions in scan time for 4D flow and segmentation time for functional analysis. While direct comparative accuracy data against all alternatives isn't detailed, it offers advanced capabilities like generating T1 and T2 maps that conventional MR images or scanners might not provide. Other AI cardiology tools include HeartFlow FFR-CT and Eko Health.
The specific pricing model for Tempus Pixel Cardio is not publicly disclosed in the provided search results. Pricing for enterprise AI solutions in healthcare is often not publicly available and may involve custom agreements or subscription models.
While the search results highlight the benefits of Tempus Pixel Cardio in improving efficiency and accuracy, explicit limitations regarding its performance in diverse patient populations or complex, atypical cases are not detailed. Generally, AI tools require ongoing validation across varied demographics, and human clinical judgment remains crucial for interpreting complex findings.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.